Name: Introducing next-generation antibodies
Uploaded: 2024-01-03T00:00:00.0000000
Duration: T00H03M31S
Description: Introducing next-generation antibodies

Name: Introducing next-generation antibodies

Description: Introducing next-generation antibodies

Thumbnail URL: https://cadmoremediastorage.blob.core.windows.net/382c6303-7981-4e36-8f7d-a2ca24461aa7/videoscrubberimages/Scrubber_1.jpg

Duration: T00H03M31S

Embed URL: https://stream.cadmore.media/player/382c6303-7981-4e36-8f7d-a2ca24461aa7

Content URL: https://cadmoreoriginalmedia.blob.core.windows.net/382c6303-7981-4e36-8f7d-a2ca24461aa7/Sino - Next-Gen Antibodies - V4.mp4?sv=2019-02-02&sr=c&sig=jBK4%2B4OxMA98T7CDXugIQK4OkHspN%2F1l98JWhGTUFQs%3D&st=2024-11-23T10%3A28%3A44Z&se=2024-11-23T12%3A33%3A44Z&sp=r

Upload Date: 2024-01-03T00:00:00.0000000

Transcript: Language: EN.
Segment:0 .
[MUSIC PLAYING]
TRISTAN FREE: The development of therapeutic monoclonal antibodies over the last three decades has been highly successful, leading to their rapid expansion in the biopharmaceutical market, and driving advances in antibody technology. These developments have led to next generation antibodies, including bispecific antibodies, antibody-drug conjugates, and nanobodies. Bispecific antibodies consist of two distinct antigen-binding sites that recognize different epitopes from the same or two different antigens.
TRISTAN FREE: Based on the presence or absence of an FC region, bispecific antibodies can be segregated into two broad subgroups-- IgG-like constructs and non-IgG-like fragments. Bispecific antibodies can implement dual targeting approaches, enable novel functionalities, enhance specificity, and increase therapeutic potency. Based on their therapeutic mechanisms of action, bispecific antibodies can be divided into four main categories-- immune effector cell redirectors, tumor-targeted immunomodulators, dual immunomodulators, and dual tumor-targeting molecules.
TRISTAN FREE: Antibody-drug conjugates or ADCs comprise a monoclonal antibody tethered to a cytotoxic drug known as the payload via a chemical linker. As a new paradigm in cancer therapy, ADCs combine the specificity of an antibody towards a tumor target antigen with the cytotoxicity of a drug. Upon specifically binding to its cellular target, the ADC antigen complex is internalized by endocytosis, after which the ADC releases its payload.
TRISTAN FREE: The free active payload then diffuses into the cytoplasm and exerts a cytotoxic effect by inhibiting microtubule assembly or damaging DNA. Additionally, membrane permeable payloads are capable of diffusing into neighboring cells regardless of target antigen expression, eliciting bystander killing which may contribute to the potency of ADCs against tumors with antigen heterogeneity. Nanobodies, also known as VHH antibodies are the single domain antigen-binding fragments derived from naturally occurring heavy chain only antibodies, first discovered in the serum of camelids.
TRISTAN FREE: With a molecular weight of around 15 kilodaltons, nanobodies are only 1/10 the size of conventional monoclonal antibodies but can retain full antigen-binding potential. Their properties include high affinity, superior stability, excellent solubility, ease of manufacturability, ability to bind to traditionally inaccessible epitopes, enhanced tumor penetration, and versatility in protein engineering.
TRISTAN FREE: Due to their numerous beneficial characteristics, nanobodies have a wide range of applications outside of therapeutics, for instance in cancer imaging. Some next generation antibodies have already been commercially approved, with many more in preclinical and clinical development. High quality bio reagents are important for therapeutic antibody development, and can be sourced from companies such as Sino Biological, who also provide custom development and production services for challenging projects.
TRISTAN FREE: To find out more about next generation antibodies, check out our in focus with Sino Biological on www.biotechniques.com. [MUSIC PLAYING]

Cadmore media player playing video Introducing next-generation antibodies

Video Player

Transcript

Segments

End of Video Player Control